Physician profile
Marisol Ramos
NPI 1881113561
$3,893.23
in general payments reported to CMS, 2019-2025
19 companies · $702 in 2025
The $702 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $927 · 2023: $1,088 · 2024: $897 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,687.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $541.32 | 2022-2024 | Ingrezza |
| Genzyme Corporation | $449.30 | 2023-2025 | |
| Alkermes, INC. | $386.19 | 2022-2024 | Lybalvi |
| Novo Nordisk INC | $323.82 | 2024-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $314.12 | 2023-2024 | Mounjaro, Jardiance |
| Abbvie INC. | $266.61 | 2021-2023 | |
| Kyowa Kirin, INC. | $241.32 | 2023-2025 | |
| Ultragenyx Pharmaceutical INC. | $221.57 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $195.01 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $128.40 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.46 | 2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $120.60 | 2023 | Eliquis |
| Ars Pharmaceuticals Operations, INC. | $105.21 | 2025 | Neffy |
| Eisai INC. | $98.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $86.08 | 2021 | |
| Viatris Specialty LLC | $82.51 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $58.22 | 2022 | |
| Hologic Sales and Service, LLC | $25.49 | 2025 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisol Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.